Gland Pharma stock surged 2 per cent in the Wednesday trading session after the pharmaceutical firm obtained approval from ...

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD) GIAPREZA of La Jolla Pharma ...

Hyderabad: Gland Pharma Limited, a generic injectable & ophthalmicfocused pharmaceutical company, has announced that the ...

New generic Multiple Sclerosis treatment option, Pr Glatiramer Acetate Injection 20 mg/mL for once-daily injection, available for one of the largest MS populations in the world Glatiramer Acetate ...

Nexafed, a tamper-resistant dosage form of the nasal decongestant pseudoephedrine, has been shown to be pharmacokinetically equivalent to Sudafed brand of the same nasal decongestant. The authors ...

Mylan N.V. has announced that it has launched the first bioequivalent alternative to GlaxoSmithKline's Seretide® Evohaler® (salmeterol xinafoate/fluticasone propionate) under the brand name Sirdupla™ ...

Please provide your email address to receive an email when new articles are posted on . Cycle Pharmaceuticals announced that the FDA has approved its Tascenso ODT, a bioequivalent to Gilenya, or ...

Many of these patients may not be aware that there's an FDA-approved, bioequivalent treatment option which is widely available. As the only FDA-approved Orally Disintegrating Tablet bioequivalent ...

Investing.com -- Glenmark Pharmaceuticals (NSE: GLEN) Inc., USA, has announced the launch of Clindamycin Phosphate Foam, 1%, a product that is bioequivalent and therapeutically equivalent to ...

They have recruited companies in low- and middle-income countries to develop a bioequivalent version. Companies will manufacture and sell the drug at a fraction of Synagis's Canadian price.

The product is bioequivalent to, but not a generic of, Gilenya ® (fingolimod) capsules. Tascenso ODT is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically ...